FREDERICK, Md., Nov. 13 /PRNewswire-FirstCall/ -- BioElectronics Corporation, , announced today that Northern Optotronics, Inc. has signed an agreement for the distribution of ActiPatch(TM) to the medical providers market in Canada. The initial order shipped on November 6, 2007.
Northern Optotronics, Inc. joins the growing list of international distributors for ActiPatch Therapy. BioElectronics has signed agreements in place and shipping has commenced to Germany, Kuwait, Singapore, Malaysia, Turkey, Columbia, the United Kingdom, Italy, the Netherlands, Panama, and Mexico. The Company expects to ship product to both Saudi Arabia and Korea by month’s end.
“We are pleased to be working with Northern Optotronics to bring the healing benefits of ActiPatch to Canadian medical market. We look forward to a long and mutually beneficial relationship”, said Andrew Whelan of BioElectronics.
“Northern Optotronics official product launch of ActiPatch began this week. We are extremely excited about the market potential for this innovative, drug-free therapy. We are planning an all out blitz to introduce ActiPatch and we expect to have significant sales revenue from ActiPatch products,” said Mr. Ross McDonald of Northern Optotronics Inc.
About Northern Optotronics:
Northern Optotronics was established in 1997 and employs 8 sales agents with a total staff of 22. The Company distributes medical/aesthetic lasers and ophthalmic products.
For more information visit http://www.noi.ca
About BioElectronics:
BioElectronics Corporation is the maker of ActiPatch(TM). ActiPatch is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for less than a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective, patient friendly method to reduce soft tissue pain and swelling.
For more information visit http://www.bioelectronicscorp.com
Safe Harbor Statement:
This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the companies have no control.
CONTACT: Andrew J. Whelan, President & CEO, +1-301-874-4890,
+1-301-874-6935 - fax, info@bioelectronicscorp.com
Web site: http://www.bioelectronicscorp.com//
